Present invention represents process for the preparation of HMG-CoA reductsase inhibitors, in particular rosuvastatin calcium introducing L-malic acid as the source of chirality for the side chain
-
Page/Page column 34
(2010/11/25)
More Articles about upstream products of 925421-90-5
Get Best Price for925421-90-5α,α-dimethylphenethyl (5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)-amino]pyrimidine-5-yl)-5-(tert-butyldimethylsilyloxy)-3-oxo-hept-6-enoate